CytomX heading into ‘major catalyst year,’ says JonesResearch

JonesResearch analyst Soumit Roy keeps a Buy rating on CytomX Therapeutics (CTMX) with a $7 price target after the company announced the new drug application submission with the FDA seeking accelerated approval for dordaviprone in the recurrent H3K27M diffuse glioma setting. If Chimerix receives priority review, an FDA action date will be set as early as Q3 of 2025, the analyst tells investors in a research note. Additionally, the firm expects topline interim survival data in Q3 from the Phase 3 trial in 1L H3K27M mutated glioma. 2025 is “shaping up to be a major catalyst year” for Chimerix, contends Jones.